AZN.L Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:36):

Stats
Šios dienos apimtis	1.64M
Vidutinė apimtis	2.95M
Rinkos kapitalizacija	185.84B
EPS	£0 ( 2024-04-24 )
Kita pelno data	( £1.550 ) 2024-07-25
Last Dividend	£71.80 ( 2023-08-10 )
Next Dividend	£0 ( N/A )
P/E	37.00
ATR14	£6.93 (0.06%)

Tūris Koreliacija

Ilgas: -0.27 (neutral)

Trumpas: 0.33 (neutral)

Signal:(74.017) Neutral

AstraZeneca PLC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

AstraZeneca PLC Koreliacija - Valiuta/Žaliavos

-0.79
( moderate negative )

-0.82
( strong negative )

-0.04
( neutral )

-0.81
( strong negative )

0.44
( neutral )

0.64
( weak )

AstraZeneca PLC Finansinės ataskaitos

Annual	2023
Pajamos:	£45.81B
Bruto pelnas:	£37.54B (81.95 %)
EPS:	£3.84

FY	2023
Pajamos:	£45.81B
Bruto pelnas:	£37.54B (81.95 %)
EPS:	£3.84

FY	2022
Pajamos:	£44.35B
Bruto pelnas:	£31.96B (72.06 %)
EPS:	£2.12

FY	2021
Pajamos:	£37.42B
Bruto pelnas:	£24.98B (66.76 %)
EPS:	£0.0854

Financial Reports:

No articles found.

AstraZeneca PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£76.40 (N/A)	£0 (N/A)	£162.80 (N/A)	£0 (N/A)	£71.80 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

AstraZeneca PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.82 - Stable (3.55%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£10.50	1993-09-20
Last Dividend	£71.80	2023-08-10
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	61	--
Total Paid Out	£3 651.80	--
Avg. Dividend % Per Year	1.07%	--
Score	4.39	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.82
Div. Directional Score	7.83	--

Next Divdend (Est)
(2024-07-01)

£70.63 Estimate 7.48 %

Dividend Stability

0.30 Very Poor

Dividend Score

4.39

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1993	£10.50	1.75%
1994	£27.75	3.38%
1995	£29.00	3.38%
1996	£32.25	2.65%
1997	£36.00	2.24%
1998	£39.00	1.87%
1999	£42.20	1.65%
2000	£44.39	1.77%
2001	£47.56	1.41%
2002	£47.90	1.55%
2003	£43.95	1.98%
2004	£45.40	1.69%
2005	£56.20	2.98%
2006	£78.40	2.73%
2007	£88.30	3.18%
2008	£95.50	4.45%
2009	£140.80	5.04%
2010	£150.30	5.11%
2011	£168.60	5.64%
2012	£181.70	5.96%
2013	£179.70	6.05%
2014	£169.90	4.78%
2015	£182.50	3.98%
2016	£199.70	4.46%
2017	£219.10	4.94%
2018	£202.00	3.96%
2019	£218.70	3.70%
2020	£216.00	2.82%
2021	£202.20	2.72%
2022	£221.70	2.62%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
VMUK.L	Dividend Junior	2023-05-18	Annually	7	1.91%
MSLH.L	Dividend Knight	2023-10-19	Annually	33	1.56%
DOCS.L	Dividend Knight	2023-06-08	Semi-Annually	3	1.23%
SIGC.L	Dividend Junior	2023-09-14	Semi-Annually	3	0.82%
IMI.L	Dividend King	2023-08-10	Semi-Annually	32	1.40%
BOY.L	Dividend King	2023-10-05	Semi-Annually	32	1.77%
ORIT.L	Dividend Knight	2023-08-17	Quarterly	5	2.77%
FAIR.L	Dividend Royal	2023-08-24	Quarterly	9	7.08%
STS.L	Dividend King	2023-10-05	Quarterly	38	1.48%
JUST.L	Dividend Royal	2023-08-24	Annually	11	93.97%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.133	1.500	7.34	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0619	1.200	7.94	9.52	[0 - 0.3]
returnOnEquityTTM	0.168	1.500	9.25	10.00	[0.1 - 1]
payoutRatioTTM	0.706	-1.000	2.94	-2.94	[0 - 1]
currentRatioTTM	0.886	0.800	-0.572	-0.458	[1 - 3]
quickRatioTTM	0.278	0.800	-3.07	-2.46	[0.8 - 2.5]
cashRatioTTM	0.271	1.500	9.60	10.00	[0.2 - 2]
debtRatioTTM	0.338	-1.500	4.37	-6.56	[0 - 0.6]
interestCoverageTTM	5.33	1.000	9.14	9.14	[3 - 30]
operatingCashFlowPerShareTTM	6.26	2.00	7.91	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.73	2.00	8.13	10.00	[0 - 20]
debtEquityRatioTTM	0.923	-1.500	6.31	-9.46	[0 - 2.5]
grossProfitMarginTTM	0.820	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.184	1.000	8.32	8.32	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.281	1.000	9.55	9.55	[0.2 - 2]
assetTurnoverTTM	0.465	0.800	-0.230	-0.184	[0.5 - 2]
Total Score				10.84

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	36.65	1.000	6.40	0	[1 - 100]
returnOnEquityTTM	0.168	2.50	9.52	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.73	2.00	8.76	10.00	[0 - 30]
dividendYielPercentageTTM	1.521	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.26	2.00	7.91	10.00	[0 - 30]
payoutRatioTTM	0.706	1.500	2.94	-2.94	[0 - 1]
pegRatioTTM	-56.45	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.204	1.000	7.41	0	[0.1 - 0.5]
Total Score				4.82

AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.